其 他 安 全 警 示
|
| |
| New safety information issued by Health Canada regarding Progressive Multifocal Leukoencephalopathy (PML) in Tysabri (natalizumab) (English only) |
| |
Biogen Idec Canada Inc., in consultation with Health Canada, inform that updated safety information regarding the risk of PML in patients receiving Tysabri (natalizumab) monotherapy is now included in the Canadian Product Monograph. Tysabri is a humanized monoclonal antibody and is currently used for the treatment of patients with relapsing-remitting multiple sclerosis. The risk of developing PML increases with increasing duration of Tysabri treatment.
Please refer to the following website in Health Canada for details:
http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2010/tysabri_3_hpc-cps-eng.php
Natalizumab is not registered in Hong Kong.
Ends/Wednesday, May 19, 2010
Issued at HKT 11:00
|
| |
|
